AƱoga, Jcel .
HRN: 21-89-73 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
09/16/2022
CEFUROXIME 500MG (TAB)
09/16/2022
09/23/2022
ORAL
500mg
BID
S/P NSVD With 2nd Degree Perineal Laceration And Repair; UTI
Waiting Final Action
Indication: Empiric Type of Infection: Reproductive Tract Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes